ACADIA Pharmaceuticals Inc.ACADNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +12.36% | +18.70% | +9.34% | +11.27% | +9.39% |
| Gross Profit Growth | +11.56% | +22.44% | +8.98% | +10.99% | +8.40% |
| EBITDA Growth | -66.64% | +7.25% | +6.97% | +50.25% | +115.69% |
| Operating Income Growth | +339.28% | +26.82% | +6.36% | +12.99% | -88.67% |
| Net Income Growth | +213.87% | +14.69% | -20.14% | +119.07% | +90.32% |
| EPS Growth | +210.71% | +10.00% | -20.00% | +115.00% | +86.21% |
| EPS Diluted Growth | +207.14% | +10.00% | -20.00% | +110.00% | +86.05% |
| Weighted Average Shares Growth | +1.05% | +1.22% | +1.37% | +1.72% | +1.68% |
| Weighted Average Shares Diluted Growth | -0.09% | +0.63% | +1.51% | +2.69% | +3.00% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -52.71% | -30.11% | +155.69% | +17.46% | -220.68% |
| Free Cash Flow Growth | -53.24% | -370.01% | +549.65% | +16.97% | -232.08% |
| Receivables Growth | +2.29% | +13.62% | +8.42% | +41.98% | +41.58% |
| Inventory Growth | -38.72% | -62.95% | -63.48% | -52.33% | +57.96% |
| Asset Growth | +58.59% | +32.42% | +34.07% | +36.23% | +31.69% |
| Book Value per Share Growth | +67.97% | +62.92% | +57.00% | +56.23% | +64.73% |
| Debt Growth | -9.11% | -6.10% | -2.36% | +11.02% | +0.37% |
| R&D Expense Growth | +50.93% | +31.14% | +2.25% | +31.86% | -15.86% |
| SG&A Expenses Growth | +16.70% | +17.02% | +14.05% | +0.08% | +19.63% |